Report Summary 1. Industry Investment Rating - The investment rating for the steel and ore industry is "Oscillating, Slightly Bullish" [1] 2. Core Viewpoints - The steel and ore market is expected to oscillate. For specific varieties, the support and pressure levels are as follows: the support level for rebar is 3000, and the pressure level is 3200; for hot - rolled coils, the support level is 3180, and the pressure level is 3350; for iron ore, the support level is 750, and the pressure level is 840 [1] 3. Summary by Directory 3.1 Market Review - On Wednesday, rebar and hot - rolled coils rose first and then fell. Both steel and ore closed down at night [1] 3.2 Important News - The National Development and Reform Commission has launched a new batch of 13 landmark major foreign - funded projects with a planned investment of $13.4 billion, focusing on manufacturing and increasing support for the service industry [1] - In January - February 2026, China's cumulative steel exports were 15.591 million tons, a year - on - year decrease of 8.1%; cumulative steel imports were 0.827 million tons, a year - on - year decrease of 21.7%; cumulative imports of iron ore and its concentrates were 210.023 million tons, a year - on - year increase of 10.0%; cumulative imports of coal and lignite were 77.222 million tons, a year - on - year increase of 1.5% [1] - In February 2026, China's steel plate exports were 4.63 million tons, a year - on - year decrease of 12.6%; cumulative exports from January - February were 9.33 million tons, a year - on - year decrease of 14.5%. In February, China's steel bar exports were 1.19 million tons, a year - on - year decrease of 7.7%; cumulative exports from January - February were 2.32 million tons, a year - on - year decrease of 5.9% [1] - Iran's largest natural gas field and some petrochemical facilities were attacked by the US and Israel, and Iran vowed to retaliate by attacking oil facilities in three Middle - Eastern countries. Qatar reported that an Iranian missile hit a natural gas hub, causing serious damage, and Iran also attacked a US - exclusive area of a refinery in Riyadh, causing a fire [1] - The Federal Reserve announced that it would maintain the federal funds rate target range between 3.5% and 3.75%, holding steady for the second consecutive time, in line with market expectations [1] 3.3 Market Logic - On the 18th, the market prices of mainstream imported iron ore varieties at Qingdao Port remained stable. For example, 60.8% PB powder was 794 (unchanged), Super Special powder was 675 (unchanged), 61.6% PB lump was 905 (unchanged), Carajas powder was 953 (unchanged), and SPGF mixed powder was 764 (unchanged) [1] - On the 17th, Shanghai Zhongtian rebar was 3260, up 10; Shanghai Angang/Benxi hot - rolled coils were 3310, up 20 [1] - On the 18th, the spot market for port coke remained stable. The trading atmosphere in the domestic spot market was average. The volume of trade shipments at the two ports was stable compared to the previous working day, and the total inventory at the two ports was stable compared to the previous working day. Rizhao Port had 43 (unchanged), Qingdao Port had 69 (unchanged), and the total inventory was 112, a decrease of 2.3 compared to last week [1] 3.4 Trading Strategies - Unilateral trading: Gradually reduce long positions in steel and ore [1] - Arbitrage trading: Continue to hold the strategy of going long on the spread between hot - rolled coils and rebar. As of the night session on Wednesday, the spread was 173. It is recommended to raise the stop - loss level to a spread of 130 and set the take - profit level at around 200 [2] - For the ratio of rebar to iron ore, which was 3.87, it is recommended to opportunistically go long on the ratio (go long on rebar and short on iron ore), with the target of raising the ratio above 4. At the same time, pay attention to the possible impact of the later main contract roll - over [2]

Group 1: Domestic News - The National Development and Reform Commission has launched a new batch of 13 major foreign investment projects with a planned investment of $13.4 billion, focusing on manufacturing sectors such as electronics, chemicals, automotive, and electrical machinery [2] - Shanghai has recognized 30 new regional headquarters of multinational companies and 15 foreign research and development centers, primarily in key industries like biomedicine, integrated circuits, high-end equipment, automotive, and fashion consumer goods [3] - Chongqing has established the first mandatory insurance mechanism for low-altitude economy, providing risk coverage of 42.6 million yuan for 194 drones operated by Aerospace Technology Group [4] Group 2: Automotive Industry - The China Passenger Car Association reported that from March 1 to 15, retail sales of passenger cars in China reached 561,000 units, a year-on-year decline of 21%, while retail sales of new energy vehicles during the same period were 285,000 units, down 28% year-on-year [5] - Chery Automobile announced a total revenue of 300.29 billion yuan for 2025, with a year-on-year growth of 11.3% and a net profit of 19.51 billion yuan, reflecting a net profit margin increase from 5.3% to 6.5% [12] - Geely Automobile reported a total revenue of 345.2 billion yuan for 2025, a year-on-year increase of 25%, with a core net profit of 14.41 billion yuan, marking a 36% growth [13] - Zotye Automobile's wholly-owned subsidiary, Zhejiang Shenkang Automotive Body Mould Co., has resumed production, although the company faces significant financial pressure and uncertainty regarding the full recovery of its vehicle business [11] Group 3: Technology and Innovation - Xiaomi's ultra-strong steel, with a strength of 2200 MPa, has won the "Science and Technology Innovation Achievement First Prize" from the China Association for the Promotion of Industry-Academia-Research Cooperation, and is now in mass production for new models [14] - GAC Toyota has initiated its first large-scale OTA upgrade for the Platinum 3X model, available for all owners free of charge [15] - The new automotive brand AISTALAND, created by Huawei and GAC, was officially announced, emphasizing the integration of AI in automotive travel [16]

Core Insights - The report highlights the ongoing adjustments in various industries, particularly in the semiconductor and photovoltaic sectors, driven by geopolitical tensions and domestic policy shifts [5][9][23]. Domestic Market Performance - The Shanghai Composite Index closed at 4,062.98, with a slight increase of 0.32%, while the Shenzhen Component Index rose by 1.05% to 14,187.80 [4]. - The average price-to-earnings ratios for the Shanghai Composite and ChiNext are 16.74 and 47.98, respectively, indicating a favorable long-term investment environment [11][12]. International Market Performance - The Dow Jones Industrial Average fell by 0.67% to 30,772.79, while the S&P 500 and Nasdaq also experienced declines of 0.45% and 0.15%, respectively [5]. - The report notes that global semiconductor sales continue to grow, with a year-on-year increase of 46.1% in January 2026, indicating strong demand in the sector [18]. Industry Analysis - The semiconductor industry is experiencing a recovery, with domestic storage module manufacturers exceeding expectations in Q1 2026, driven by rising prices in the global market [17]. - The photovoltaic industry is undergoing a significant adjustment phase, with a focus on reducing internal competition and enhancing value through technological advancements [34][36]. Investment Recommendations - The report suggests focusing on sectors such as communication equipment, semiconductors, and IT services for short-term investment opportunities, given their current performance and market conditions [10][11]. - In the food and beverage sector, investment opportunities are identified in upstream raw material companies, particularly as inflationary pressures shift investment focus from oil and chemicals to agricultural products [28][30].

Core Viewpoint - The article discusses a groundbreaking study on mitochondrial transplantation, which presents a new therapeutic approach for mitochondrial diseases and neurodegenerative disorders such as Parkinson's disease, leveraging encapsulated mitochondria for effective treatment [4][6][10]. Group 1: Research Findings - The study developed a new technique for mitochondrial encapsulation, allowing for efficient in vivo transplantation of mitochondria, significantly improving symptoms in models of Parkinson's disease, Leigh syndrome, and mitochondrial DNA depletion syndrome [5][10]. - The research introduces the concept of "organelle therapy," providing a novel treatment strategy for mitochondrial genetic diseases and neurodegenerative disorders [6][10]. - The encapsulation method utilizes red blood cell membranes to create "mitochondrial capsules," which protect the mitochondria and enhance their delivery into recipient cells, achieving a transplantation efficiency of approximately 80% compared to less than 5% for bare mitochondria [7][10]. Group 2: Implications and Applications - Mitochondrial transplantation can repair mitochondrial defects in patient-derived cells and is effective in treating mitochondrial DNA depletion syndrome and Leigh syndrome [8][10]. - In mouse models of Parkinson's disease, mitochondrial transplantation effectively prevented neuronal death and restored normal mitochondrial function, significantly improving motor abilities [10][11]. - This organelle therapy approach offers a more precise strategy compared to traditional cell therapies, potentially benefiting a wide range of diseases associated with mitochondrial dysfunction, including neurodegenerative diseases and metabolic disorders [10][11].

Core Viewpoint - The National Development and Reform Commission (NDRC) has launched a new batch of 13 significant foreign investment projects with a planned investment of $13.4 billion, focusing on manufacturing and increasing support for the service sector, including logistics for the first time [3][5]. Group 1: Investment Projects - The newly selected projects are primarily concentrated in manufacturing sectors such as electronics, chemicals, automotive, and electrical machinery, promoting the accelerated development of industrial clusters [5]. - The cumulative investment in significant foreign investment projects has reached $108 billion, demonstrating a notable demonstration effect in attracting foreign capital [3]. Group 2: Policy and Market Environment - The NDRC aims to expand market access and open fields with a focus on the service sector, enhancing the attractiveness of foreign investment in advanced manufacturing, modern services, high-tech, and energy-saving sectors [3][9]. - The government work report for this year emphasizes the need to deepen reforms in the foreign investment promotion system, ensuring national treatment for foreign enterprises and promoting local production [9][11]. Group 3: Foreign Investment Trends - Recent data indicates that nearly 60% of surveyed U.S. companies plan to increase their investment in China, reflecting China's long-term attractiveness as a fertile ground for foreign investment [6]. - The NDRC and the Ministry of Commerce have released the "Encouragement Directory for Foreign Investment (2025 Edition)," effective from February 1, 2026, to guide foreign investment towards advanced manufacturing and modern services [10]. Group 4: Regional Initiatives - Various regions, including Shanghai, Shandong, and Jiangsu, are actively deploying strategies to stabilize foreign investment, focusing on project implementation and enhancing service guarantees for foreign enterprises [12][13]. - Shanghai has prioritized manufacturing investment, aiming to build a modern industrial system around advanced manufacturing, with ongoing efforts to attract global resources and enhance project landing [13].

Group 1 - The article discusses the upcoming Guotai Haitong Spring Strategy Conference scheduled for March 25, 2026, in Shenzhen, focusing on innovative breakthroughs and global value opportunities [1] - Key topics include the exploration of long-term precise weight loss and metabolic benefits through a new generation RNAi technology platform, presented by Meng Na, Vice President of Capital Markets at Saint Gene Biotech [1] - Other presentations will cover applications and prospects of brain-machine interfaces and neuro-regulation medical technologies, as well as advancements in lipid management through small nucleic acid drugs, presented by industry experts [1]

Core Viewpoint - Zhengxiang Pharmaceutical (Nanjing) Group Co., Ltd. has submitted an IPO application to the Hong Kong Stock Exchange, aiming to raise capital to address its development challenges, primarily relying on its core product, the novel influenza drug "Marcilosavir Tablets" [1][2] Group 1: Product Overview - "Marcilosavir Tablets," approved by the National Medical Products Administration in July 2025, is a new generation of targeted influenza virus RNA polymerase PA inhibitors, representing one of four domestic influenza drugs approved for market entry [1][2] - The product is priced at 222 RMB per box, making it the most expensive domestic influenza innovation drug [1] - The actual sales performance of "Marcilosavir Tablets" post-approval is not included in the prospectus, limiting investors' ability to assess its market competitiveness and commercial potential [2] Group 2: Market Competition - The influenza drug market is becoming increasingly competitive, with multiple new domestic drugs approved in 2025, including those from Qingfeng Pharmaceutical and Zhongsheng Pharmaceutical, which have already entered the National Medical Insurance Directory [3] - "Marcilosavir Tablets" has not yet entered the insurance directory, putting it at a disadvantage in terms of price competition [3] - Traditional antiviral drug Oseltamivir remains the mainstream choice in the grassroots market, further constraining the market space for "Marcilosavir Tablets" [3] Group 3: Commercialization Challenges - Zhengxiang Pharmaceutical lacks a dedicated sales team, relying entirely on a partnership with Jichuan Pharmaceutical for the commercialization of "Marcilosavir Tablets" [3][4] - The exclusive sales agreement with Jichuan Pharmaceutical includes a significant upfront payment and ongoing service fees based on sales, which may compress profit margins and limit control over market channels [4] Group 4: Financial Situation - As of September 30, 2025, Zhengxiang Pharmaceutical reported total liabilities of approximately 1.26 billion RMB, with a debt-to-asset ratio of 415.84%, indicating severe financial strain [10] - The company has been operating at a loss, with a net loss of 145.4 million RMB in 2024 and a similar loss in the first nine months of 2025, leading to cumulative losses exceeding 400 million RMB since its inception [8][10] - High R&D costs, which accounted for over 82% of total costs, coupled with low revenue, have created a cycle of high investment and low output, exacerbating financial difficulties [8][11] Group 5: Future Outlook - The IPO is seen as a critical move for survival amid financial pressures, with potential consequences including funding shortages and operational disruptions if the listing fails [11] - The company must enhance the market competitiveness of its core product and diversify its R&D pipeline to achieve sustainable growth rather than relying solely on the IPO to alleviate short-term financial pressures [11]

Core Viewpoint - The National Development and Reform Commission has launched a new batch of 13 significant foreign investment projects with a planned investment of $13.4 billion, primarily focusing on the manufacturing sector and modern service industries [1][2] Group 1: Investment Projects - The new projects are concentrated in manufacturing, including electronic manufacturing, chemicals, automotive, and electrical machinery, aimed at accelerating the development of industrial clusters [1] - For the first time, logistics projects have been included in the list, alongside continued support for research and development centers in the biopharmaceutical sector [1] Group 2: Investment Impact - To date, the cumulative investment in significant foreign investment projects has reached $108 billion, demonstrating a notable引资示范带动效应 [2]

Group 1 - Zhipu AI (02513) saw a price increase of over 10% during trading, currently up 7.4%, following the announcement of its first closed-source model GLM-5-Turbo and a 20% price hike for its new model API [1] - Capital Airport (00694) dropped over 4% after JPMorgan downgraded its investment rating from "Neutral" to "Underweight" and cut the target price by 40% to HKD 1.8, citing structural challenges and potential selling pressure from being removed from the Hong Kong Stock Connect list [1] - Cloudwalk Technology (02670) rose over 7% after signing a strategic cooperation agreement with SF Express to define new standards for building delivery [1] Group 2 - Yiming Anke-B (01541) increased by over 8% after receiving approval for its II phase clinical study of IMM0306 for treating Primary Membranous Nephropathy [2] - WanGuo Data-SW (09698) surged over 12.6% after reporting a net revenue of RMB 11.4323 billion (USD 1.6348 billion) for the year, a 10.8% year-on-year increase, with adjusted EBITDA also up by 10.8% [2] - Automotive stocks collectively fell, with Li Auto-W (02015) down 6.24%, Xpeng Motors-W (09868) down 4.35%, and Great Wall Motors (02333) down 2.64%, amid warnings from multiple CEOs about rising chip costs [2] Group 3 - Smoore International (06969) opened slightly higher but fell 15.21% after reporting a revenue of approximately RMB 14.256 billion for 2025, a 20.8% increase, but a net profit decline of 18.5% [3] - China Cosco Shipping Energy Transportation (01138) rose 5.39% as reports indicated significant impacts on the tanker and energy markets due to ongoing Middle East conflicts [3] Group 4 - China Oriental Education (00667) increased by 6.57% after reporting a revenue of RMB 4.616 billion for 2025, a 12.1% year-on-year increase, with net profit up 47.5% [4] - Changfeng Pharmaceutical (02652) surged over 21%, currently up 9.99%, after announcing the acceptance of its IND application for a new inhalation powder for treating pulmonary arterial hypertension [4] Group 5 - Swarmer (SWMR.US) debuted on the US stock market with a staggering opening price increase of 315.4%, currently up 520%, focusing on AI-driven drone swarm control systems [5] - 36Kr (KRKR.US) rose 37.39% after reporting a total revenue of RMB 227 million for 2025, with a gross margin increase to 58% and a net profit of approximately RMB 11.42 million [5] - Space-related stocks saw active trading, with Rocket Lab (RKLB.US) up 10.21% and Planet Labs PBC (PL.US) up 10.08% [5] Group 6 - Solaris Energy Infrastructure (SEI.US) rose 10.88% after announcing agreements worth USD 620 million to add approximately 900 MW of gas turbine capacity between 2026 and 2029 [7] - Uber (UBER.US) increased by 4.19% following a partnership with NVIDIA to deploy autonomous taxi fleets in major US cities by 2027 [8] - Aiko Solar (CSIQ.US) rose 1.94% after announcing a supply agreement for a 500 MW energy storage project [8] - Atour (ATAT.US) saw a price increase of 5.98% after reporting a net revenue of approximately RMB 2.788 billion for Q4 2025, a 33.8% year-on-year increase [8]

Summary of Key Points from the Conference Call Industry Overview - The conference call discusses the **biomedical industry** in China, highlighting its elevation as a new pillar industry in the national development plan, particularly focusing on **biomanufacturing, brain-computer interfaces, high-end medical devices, and innovative drug development** [1][2]. Core Insights and Arguments - **Policy Direction**: The top-level design of the biomedical industry policy emphasizes two core directions: "strong innovation" and "benefiting people's livelihood." The industry is recognized for its economic importance and social function, with a focus on improving the healthcare system [2][3]. - **Medicare Adjustments**: In 2026, the per capita financial subsidy for Medicare is planned to increase by **24 yuan**, a slight decrease from the **30 yuan** increase in 2025, indicating a continued trend of increasing government subsidies despite a slight adjustment in growth rate [2]. - **Support for Innovative Drugs**: The 2025 Medicare drug list adjustment reflects strong support for "true innovation," with **40%** of the newly added **114 drugs** being first-class new drugs, and **50%** of these being biological products [5][6]. - **Renewal Rules**: The renewal rules for drugs in the Medicare directory show a stable support attitude towards high-value mature products, with **92%** of drugs renewing without price reductions [6]. - **Commercial Insurance Directory**: The first commercial insurance directory introduced in 2025 included **19 out of 141** reported drugs, focusing on high-innovation products and offering significant policy benefits [7][8]. - **Accelerating Domestic Drug Access**: Measures have been taken to accelerate the access of domestic innovative drugs to hospitals, including a requirement for medical institutions to hold drug committee meetings within **three months** of the Medicare directory release [9]. Additional Important Content - **Consolidation in Retail Pharmacy**: The retail pharmacy industry is expected to enter a phase of high-quality development and horizontal mergers starting in 2026, with policies encouraging pharmacies to execute equal outpatient insurance treatment as grassroots medical institutions [11]. - **IVD Sector Developments**: The IVD sector is seeing significant changes, including a focus on reducing the number of chargeable items and ensuring that AI-assisted diagnostics do not incur additional fees [17][18]. - **Medical Device Industry Trends**: The medical device industry is experiencing a slowdown in bidding procurement growth, with an expansion of centralized procurement covering about **30%** of the industry, particularly in county-level medical communities [19][20]. - **Medicare Payment Reform**: The upcoming **DRG/DIP 3.0** version is expected to provide more specific support for innovation, while a nationwide pilot for traditional Chinese medicine payment by disease will also be initiated [20][21]. - **Regulatory Changes**: New regulatory measures are being implemented to enhance the efficiency of Medicare fund clearing and to apply AI technology in regulatory processes [22]. This summary encapsulates the key points discussed in the conference call, providing insights into the current state and future direction of the biomedical industry in China.